Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?

24.03.25 14:40 Uhr

Werte in diesem Artikel
Aktien

23,00 EUR -0,58 EUR -2,44%

646,00 JPY 1,00 JPY 0,16%

Indizes

PKT PKT

PKT PKT

1.951,5 PKT -18,8 PKT -0,95%

2.024,5 PKT -24,8 PKT -1,21%

22.860,0 PKT -249,8 PKT -1,08%

8.746,1 PKT -106,3 PKT -1,20%

1.716,1 PKT -25,1 PKT -1,44%

523,4 PKT -1,3 PKT -0,24%

206,1 PKT -0,5 PKT -0,24%

559,9 PKT -4,7 PKT -0,83%

5.422,3 PKT -52,8 PKT -0,96%

11.960,4 PKT -106,8 PKT -0,89%

22.903,5 PKT -259,5 PKT -1,12%

23.200,5 PKT 67,7 PKT 0,29%

16.919,5 PKT -45,0 PKT -0,27%

8.832,3 PKT -87,3 PKT -0,98%

23.193,5 PKT 54,2 PKT 0,23%

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1011 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for BAYRY's full-year earnings has moved 5.3% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the latest available data, BAYRY has gained about 33.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Bayer Aktiengesellschaft is outperforming the sector as a whole this year.Enhabit (EHAB) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.9%.In Enhabit's case, the consensus EPS estimate for the current year increased 32.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 12 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 6.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns.On the other hand, Enhabit belongs to the Medical Services industry. This 59-stock industry is currently ranked #77. The industry has moved +5.2% year to date.Going forward, investors interested in Medical stocks should continue to pay close attention to Bayer Aktiengesellschaft and Enhabit as they could maintain their solid performance.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report Enhabit, Inc. (EHAB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Bayer

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bayer

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Bayer

Wer­bung

Analysen zu Bayer

DatumRatingAnalyst
12:06Bayer KaufenDZ BANK
24.03.2025Bayer NeutralGoldman Sachs Group Inc.
24.03.2025Bayer NeutralJP Morgan Chase & Co.
20.03.2025Bayer Market-PerformBernstein Research
17.03.2025Bayer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
12:06Bayer KaufenDZ BANK
27.11.2024Bayer KaufenDZ BANK
14.11.2024Bayer KaufenDZ BANK
06.08.2024Bayer KaufenDZ BANK
06.06.2024Bayer KaufenDZ BANK
DatumRatingAnalyst
24.03.2025Bayer NeutralGoldman Sachs Group Inc.
24.03.2025Bayer NeutralJP Morgan Chase & Co.
20.03.2025Bayer Market-PerformBernstein Research
17.03.2025Bayer NeutralJP Morgan Chase & Co.
11.03.2025Bayer NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
31.10.2019Bayer VerkaufenIndependent Research GmbH
21.08.2019Bayer VerkaufenIndependent Research GmbH
01.08.2019Bayer VerkaufenIndependent Research GmbH
28.06.2019Bayer VerkaufenIndependent Research GmbH
25.04.2019Bayer VerkaufenIndependent Research GmbH

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bayer nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen